<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359853</url>
  </required_header>
  <id_info>
    <org_study_id>00-pbe-mnjf-2</org_study_id>
    <nct_id>NCT00359853</nct_id>
  </id_info>
  <brief_title>Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis</brief_title>
  <official_title>Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <brief_summary>
    <textblock>
      Advanced liver disease and low ascitic fluid protein concentration have been identified as
      risk factors for spontaneous bacterial peritonitis in cirrhosis. Moreover, renal impairment
      and hyponatremia increase mortality rate of this infection. Aims: To investigate if oral
      administration of norfloxacin prevents the first episode of SBP, hepatorenal syndrome and
      improves survival in cirrhotic patients with ascites and low protein concentration in ascitic
      fluid (&lt;15 g/L) and at least one of the following inclusion criteria: functional renal
      failure (serum creatinine ≥ 1,2 mg/dl or BUN ≥ 25 mg/dl), hyponatremia (serum sodium ≤ 130
      mEq/L) or advanced liver disease (Child ≥ 9 points with serum bilirubin ≥ 3 mg/dl). Methods:
      Prospective, multicenter, randomized, double-blind placebo controlled trial comparing oral
      norfloxacin (400 mg/d; n=35) with placebo (n=35).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date>March 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term and long-term survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of the first episode of spontaneous bacterial peritonitis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of hepatorenal syndrome</measure>
  </secondary_outcome>
  <enrollment>70</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <condition>Hepatorenal Syndrome</condition>
  <condition>Cirrhosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral norfloxacin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years, protein concentration in ascitic fluid &lt; 15 g/L and at least one of
             the following: serum creatinine ≥ 1.2 mg/dl or BUN ≥ 25 mg/dl, serum sodium ≤ 130
             mEq/L or severe liver failure as defined by a Child-Pugh score ≥ 9 points and a serum
             bilirubin ≥ 3 mg/dl.

        Exclusion Criteria:

          -  Previous history of spontaneous bacterial peritonitis or of norfloxacin prophylaxis,
             allergy to quinolones, hepatocellular carcinoma, organic renal failure and HIV
             infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miquel Navasa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver Unit. Hospital Clinic Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2006</study_first_submitted>
  <study_first_submitted_qc>August 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2006</study_first_posted>
  <last_update_submitted>August 1, 2006</last_update_submitted>
  <last_update_submitted_qc>August 1, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2006</last_update_posted>
  <keyword>Norfloxacin, primary prophylaxis, SBP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norfloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

